Last edition
News about "RAFT Shareholders"
GSK will acquire RAPT Therapeutics for USD 2.2 billion, adding phase IIb anti-IgE antibody ozureprubart to its pipeline, targeting long-acting protection for patients with severe food allergies.
RAFT Shareholders | 20/01/2026 | By News Bureau | 111
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members